Heather L. McArthur

9.9k citations

146 papers · 2.7k indexed · 1 hit paper · h-index 28

Oncology top 1%
- Cancer Immunotherapy and Biomarkers 70
- HER2/EGFR in Cancer Research 48
- Cancer Treatment and Pharmacology 34
- Cancer Cells and Metastasis 13
Cancer Research top 2%
- Breast Cancer Treatment Studies 40
- Cancer Genomics and Diagnostics 16
Immunology top 5%
- Immunotherapy and Immune Responses 15
Radiology, Nuclear Medicine and Imaging top 2%
Pulmonary and Respiratory Medicine top 5%
- Advanced Breast Cancer Therapies 29

Co-authors: Alice Y. Ho Clifford A. Hudis Zishuo I. Hu David B. Page Patrick G. Morris Sujata Patil Gary A. Ulaner Maura N. Dickler
Cited by: Oncology Cancer Research Immunology
Partner nations: United States United Kingdom Germany

In The Last Decade

Heather L. McArthur

137 papers receiving 2.7k citations

Hit Papers

align trajectories log scale

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2024 Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522

Peers

Countries citing papers authored by Heather L. McArthur

Since Specialization

Citations

This map shows the geographic impact of Heather L. McArthur's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Heather L. McArthur with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Heather L. McArthur more than expected).

Fields of papers citing papers by Heather L. McArthur

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Heather L. McArthur. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Heather L. McArthur. The network helps show where Heather L. McArthur may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Heather L. McArthur, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Heather L. McArthur Line = papers co-authored together Heather L. McArthur links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Factors Associated with Nodal Positivity Following Neoadjuvant Systemic Therapy in Breast Cancer Patients Who are Initially Node-Negative on MRI B. Bersu Ozcan,Firouzeh K. Arjmandi,Dogan S. Polat,Yin Xi,Sunati Sahoo,Marilyn Leitch,Heather L. McArthur,Başak E. Doğan	2025	0
2	Event-free survival by residual cancer burden with pembrolizumab in early-stage TNBC: exploratory analysis from KEYNOTE-522breakdown → Lajos Pusztai,Carsten Denkert,Joyce O’Shaughnessy,Javier Cortés,Rebecca Dent,Heather L. McArthur,Sherko Kümmel,Jonas Bergh,Y.H. Park,Rina Hui,Nadia Harbeck,Masato Takahashi,Michael Untch,Peter A. Fasching,Fátima Cardoso,Ying Zhu,Wilbur Pan,Konstantinos Tryfonidis,Peter Schmid	2024	47
3	Impact of neoadjuvant pembrolizumab adherence on pathologic complete response in triple-negative breast cancer: a real-world analysis Alexis LeVee,Megan Wong,Sarah Flores,Nora Ruel,Heather L. McArthur,James Waisman,Joanne Mortimer	2024	9
4	LBA19 Capivasertib (C) + paclitaxel (P) as first-line treatment of metastatic triple-negative breast cancer (mTNBC): The CAPItello-290 phase III trial Peter Schmid,Heather L. McArthur,J. Cortés,Baojun Xu,F. Cardoso,M.L. Casalnuovo,Utkan Demirci,Rui Freitas,Jaya Ghosh,Roberto Hegg,Hiroaki Iwata,Yamil Alonso Lopez Chuken,M. Nechaeva,Mark E. Robson,Ricardo Villalobos-Valencia,Andrew Lloyd,Celina M. D’Cruz,Andrew Foxley,Y.H. Park	2024	5
5	Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(−) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice Manali Bhave,Júlia C.F. Quintanilha,Hanna Tukachinsky,Gerald Li,Takara Scott,Jeffrey S. Ross,Lincoln W. Pasquina,Richard S.P. Huang,Heather L. McArthur,Mia Levy,Ryon P. Graf,Kevin Kalinsky	2024	11
6	PEARL: A Phase Ib/II Biomarker Study of Adding Radiation Therapy to Pembrolizumab Before Neoadjuvant Chemotherapy in Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer Alice Y. Ho,Stephen L. Shiao,Samantha A. Kobald,Jonathan Chen,Dan G. Duda,Amy Ly,Veerle Bossuyt,Hae Lin Cho,Brittany Arnold,Simon Knott,Gaorav P. Gupta,Philomena McAndrew,Scott Karlan,Mourad Tighiouart,Alona Muzikansky,Reva Basho,Heather L. McArthur	2024	6
7	Digital droplet PCR analysis of organoids generated from mouse mammary tumors demonstrates proof-of-concept capture of tumor heterogeneity Katherine E. Lake,Megan M Colonnetta,Clayton Smith,Kaitlyn Saunders,Kenneth Martinez-Algarin,Sakshi Mohta,Jacob Pena,Heather L. McArthur,Sangeetha M. Reddy,Evanthia T. Roussos Torres,Elizabeth H. Chen,Isaac S. Chan	2024	1
8	LBA18 Pembrolizumab or placebo plus chemotherapy followed by pembrolizumab or placebo for early-stage TNBC: Updated EFS results from the phase III KEYNOTE-522 study Peter Schmid,Javier Cortés,Rebecca Dent,Lajos Pusztai,Heather L. McArthur,Sherko Kümmel,Carsten Denkert,Y.H. Park,Rina Hui,N. Harbeck,M. Takahashi,Theodoros Foukakis,M.A. Mouret Reynier,M.I.R. Ferreira,S-A. Im,Fátima Cardoso,Yu Ding,W. Pan,Konstantinos Tryfonidis,Joyce O’Shaughnessy	2023	20
9	LBA21 KEYNOTE-756: Phase III study of neoadjuvant pembrolizumab (pembro) or placebo (pbo) + chemotherapy (chemo), followed by adjuvant pembro or pbo + endocrine therapy (ET) for early-stage high-risk ER+/HER2– breast cancer Fátima Cardoso,Heather L. McArthur,Peter Schmid,Javier Cortés,Nadia Harbeck,Melinda L. Telli,David W. Cescon,Joyce O’Shaughnessy,Peter A. Fasching,Zhi-Min Shao,Delphine Loirat,Y.H. Park,María Ángeles Fernández,Z. Liu,Hiroyuki Yasojima,Yu Ding,L. Jia,Vassiliki Karantza,Konstantinos Tryfonidis,Aditya Bardia	2023	67
10	Brain radiotherapy, tremelimumab-mediated CTLA-4-directed blockade +/− trastuzumab in patients with breast cancer brain metastases David B. Page,Kathryn Beal,Stefanie N. Linch,Kateri J. Spinelli,Micaela Rodine,Darragh Halpenny,Shanu Modi,Sujata Patil,Robert J. Young,Thomas Kaley,Taha Merghoub,David Redmond,Phillip Wong,Christopher A. Barker,Adi Diab,Larry Norton,Heather L. McArthur	2022	25
11	1O KEYNOTE-522 Asian subgroup: Phase III study of neoadjuvant pembrolizumab (pembro) vs placebo (pbo) + chemotherapy (chemo) followed by adjuvant pembro vs pbo for early triple-negative breast cancer (TNBC) Rebecca Dent,Javier Cortés,Lajos Pusztai,Heather L. McArthur,Sherko Küemmel,Jonas Bergh,Carsten Denkert,Y.H. Park,Rina Hui,Nadia Harbeck,Masato Takahashi,Theodoros Foukakis,Peter A. Fasching,Fátima Cardoso,L. Jia,E. Jensen,Vassiliki Karantza,Gursel Aktan,Joyce O’Shaughnessy,Peter Schmid	2020	7
12	KEYNOTE-522: Phase III study of pembrolizumab (pembro) + chemotherapy (chemo) vs placebo + chemo as neoadjuvant followed by pembro vs placebo as adjuvant therapy for triple-negative breast cancer (TNBC) Peter Schmid,J. Cortés Castán,Jonas Bergh,Lajos Pusztai,Carsten Denkert,Sunil Verma,Heather L. McArthur,Jing Zhao,Gursel Aktan,T. Dang,Rebecca Dent	2017	5
13	A single-arm, phase ii study assessing the efficacy of pembrolizumab (pembro) plus radiotherapy (RT) in metastatic triple negative breast cancer (mTNBC) Heather L. McArthur,Christopher A. Barker,Ayca Gucalp,L Zapata,Yuetao Wen,A. Phung,M. Wilgucki,M Henrich,Brittany Arnold,Z. Zhang,Allen S. Ho	2017	13
14	Detection of HER2-Positive Metastases in Patients with HER2-Negative Primary Breast Cancer Using ⁸⁹Zr-Trastuzumab PET/CT Gary A. Ulaner,David M. Hyman,Dara S. Ross,Adriana Corben,Sarat Chandarlapaty,Shari Goldfarb,Heather L. McArthur,Joseph P. Erinjeri,Stephen B. Solomon,H. Kolb,Serge K. Lyashchenko,Jason S. Lewis,Jorge A. Carrasquillo	2016	144
15	Phase IB Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Women with Hormone Receptor–Negative Breast Cancer Katherine D. Crew,Powel H. Brown,Heather Greenlee,Therese B. Bevers,Banu Arun,Clifford A. Hudis,Heather L. McArthur,Jenny C. Chang,Mothaffar F. Rimawi,Lana A. Vornik,Terri L. Cornelison,Antai Wang,Hanina Hibshoosh,Aqeel Ahmed,Mary Beth Terry,Regina M. Santella,Scott M. Lippman,Dawn L. Hershman	2012	76
16	Adjuvant trastuzumab reduces locoregional recurrence in women who receive breast‐conservation therapy for lymph node‐negative, human epidermal growth factor receptor 2‐positive breast cancer Ana P. Kiess,Heather L. McArthur,Kathleen M. Mahoney,Sujata Patil,Patrick G. Morris,Alice Y. Ho,Clifford A. Hudis,Beryl McCormick	2011	70
17	Aromatase inhibitor strategies in metastatic breast cancer Heather L. McArthur,Patrick G. Morris	2009	2
18	An overview of HER-targeted therapy with lapatinib in breast cancer Heather L. McArthur	2009	13
19	Risk of early recurrence among postmenopausal women with estrogen receptor‐positive early breast cancer treated with adjuvant tamoxifen Hagen Kennecke,Heather L. McArthur,Ivo A. Olivotto,Caroline Speers,Chris Bajdik,Stephen Chia,Susan Ellard,B. Norris,Malcolm Hayes,Jeff Barnett,Karen A. Gelmon	2008	34
20	Breast Cancer Chemotherapy Heather L. McArthur,Clifford A. Hudis	2007	16

About Heather L. McArthur

Heather L. McArthur is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine, having authored 146 papers that have together received 2.7k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (70 papers), HER2/EGFR in Cancer Research (48 papers), Breast Cancer Treatment Studies (40 papers), Cancer Treatment and Pharmacology (34 papers), Advanced Breast Cancer Therapies (29 papers), Cancer Genomics and Diagnostics (16 papers), Immunotherapy and Immune Responses (15 papers) and Cancer Cells and Metastasis (13 papers). The work is most often cited by research in Oncology (1.8k citations), Cancer Research (800 citations) and Immunology (589 citations). Heather L. McArthur has collaborated with scholars based in United States, United Kingdom and Germany. Frequent co-authors include Alice Y. Ho, Clifford A. Hudis, Zishuo I. Hu, David B. Page, Patrick G. Morris, Sujata Patil, Gary A. Ulaner, Maura N. Dickler, Maxine S. Jochelson and Larry Norton.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact